Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$53.67
pos +0.47
+0.88%
Today's Range: 53.47 - 53.96 | TEVA Avg Daily Volume: 5,567,900
Last Update: 08/24/16 - 10:09 AM EDT
Volume: 242,825
YTD Performance: -18.95%
Open: $53.53
Previous Close: $53.20
52 Week Range: $48.01 - $66.58
Oustanding Shares: 914,000,000
Market Cap: 48,880,720,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 12 12 12
Moderate Buy 2 2 2 2
Hold 5 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.72 1.53 1.53 1.53
Latest Dividend: 0.29
Latest Dividend Yield: 2.16%
Dividend Ex-Date: 08/18/16
Price Earnings Ratio: 29.38
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
29.38 27.80 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.87% -20.50% 38.90%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 0.00 -0.01
Net Income -47.50 -0.20 -0.06
EPS -48.90 -0.20 -0.06
Earnings for TEVA:
EBITDA 5.79B
Revenue 19.65B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.32 $1.42 $5.20 $5.95
Number of Analysts 4 4 7 7
High Estimate $1.39 $1.44 $5.28 $6.21
Low Estimate $1.29 $1.41 $5.12 $5.24
Prior Year $1.35 $1.28 $5.42 $5.20
Growth Rate (Year over Year) -2.22% 10.94% -4.09% 14.48%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week.
AAP portfolio managers Cramer and Mohr defend the drug company after it tops analysts' bottom-line expectations while missing top-line estimates.
Bearish
Aug 05, 2016 | 7:53 AM EDT
TEVA was downgraded from Outperform to Perform, Oppenheimer said. Company is facing a "toss-up" over the pending decision of Copaxone p...
Rarely do investors get to buy these types of quality businesses at such discounted prices.
Deal rumors are deflating, but a takeover bid could reward holdouts.
An investor should make good money on any turn in the drug maker's business or in investor sentiment.
The stock has broken free of tiresome resistance in a big way.
I expect Allergan or another player to bid for SGYP soon.
Bearish
Jul 15, 2016 | 7:15 AM EDT
TEVA was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $60 price target.
The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.

Columnist Conversations

Tesla (TSLA) shares can accelerate forward really quickly and then go into reverse equally as fast, just take...
The government bought 11 million pounds of excess cheese. http://www.businessinsider.com/us-government-buyi...
Here's a link to some very good information for all investors. http://tonyisola.com/2016/08/the-united-...
A breakout is underway on the weekly chart of the New York Times Company (NYT) with shares penetrating a ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.